Avadel Pharmaceuticals PLC (AVDL NASDAQ) stock market data APIs
$8.6875
-0.26(-3%)
as of April 25, 2025
Avadel Pharmaceuticals PLC Financial Data Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Prev. Close
8.6875
Open
8.4271
High
8.7988
Low
8.4013
52 wk Range
6.38-19.09
Market Cap
847 M
Shares Outstanding
96 629 K
Revenue
169 M
EPS
-0.05
Beta
1.632
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avadel Pharmaceuticals PLC data using free add-ons & libraries
Get Avadel Pharmaceuticals PLC Fundamental Data
Avadel Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 169 M
- EBITDA: -39 718 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-03
- EPS/Forecast: -0.0376
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avadel Pharmaceuticals PLC News
New
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
Avadel Pharmaceuticals plc -- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patient...
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse Avadel Pharmaceuticals plc's (NASDAQ:AVDL) business as it appears the company may be on the cusp of a considerable accomplishment. Avadel Pharmaceuticals p...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals plc DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
